Notification icon

Series A funding round opening soon.

Read More
/
Investors

The time for Phages &
Smart Software Is Now!

Join us in leading the way in converging biology and computation.
precisionphage for investors

Series A Funding Round Opening Soon

PrecisionPhage is preparing to launch its Series A funding round, opening new opportunities to scale our technology and global impact. This round will enable us to further focus on:

  • Innovation: Expanding our software suite for genomic analysis
  • Scale: Strengthening scalable computational infrastructure
  • Impact: Advancing antimicrobial resistance (AMR) solutions worldwide
  • Growth: Driving commercialization of data-driven biotechnology

Interested? Contact us now!

Contact Us
Download Teaser Deck
Why Phages?

Phages are The Future of Infection Control and Treatment

Phages offer a revolutionary approach to combating antibiotic resistance. Their specificity and efficacy make them invaluable in modern medicine.

bacteria icon

Desperate need

AMR is one the most pressing issues facing humanity.

Targeted therapy

Phages offer a huge leap forward in personalised healthcare.

Global utilization increasing

AMR knows no borders.

Versatile opportunities

Phages offer a foundation for multiple infection treatment opportunities and solutions beyond healthcare.

Contact Us
Short Video about Phages
bacteriophage solutions for healthcare
man developoing bacteriophage software
Why us?

Driving Growth Through Bioinformatics & Software

Our approach positions us strongly at one of the fastest-growing intersections: the one between biology and computation. By developing advanced software solutions supported by our unique licensing and laboratory assets, we are creating scalable technologies that serve both immediate industry needs and long-term innovation.

Scalable digital platforms

Our software supports a variety of users from smaller activities to large-scale industry operations.

GMP-compliant solutions

We are developing regulatory-ready digital tools to address a critical need in regulated manufacturing environments.

Cross-industry impact

Our software is not limited to healthcare as it can be adapted for industrial biotech, agriculture, food safety, and beyond.

AI and machine learning potential

By exploring AI-driven approaches, we open doors to next-generation innovation.

Contact Us
Return

By investing in us, you gain access to:

Strong academic foundation and culture of innovation

We are rooted in rigorous science and continually push the boundaries of research and development, transforming bold ideas into practical solutions.

Opportunity

Be part of a sector that bridges life sciences with digital transformation — one that is expanding rapidly as computation and biology converge.

Vast resources

With a diverse phage library and a scalable computational infrastructure, we are uniquely positioned to deliver results at speed and scale.

Global impact

Our solutions address worldwide challenges, from antimicrobial resistance to industrial biotechnology, creating growth opportunities across multiple sectors.

Contact Us
three precisionphage employees

Let’s shape the future of biotechnology together!

Founded

2022

Vision

Tomorrow

Time to act

Now

Don’t hesitate to

Contact Us
Insights

Latest News for Investors

Articles
Apr 1, 2025

PrecisionPhage’s Solutions Built on 40+ Years of Combined Experience in Phage Research

PrecisionPhage is an academically rooted company at the forefront of bacteriophage research and applications. The company's team comprises specialists from Finnish universities and international institutions. Our extensive research portfolio underpins PrecisionPhage's mission to develop high-quality applications for combating antibiotic-resistant infections.
Read more
News
Nov 12, 2024

PrecisionPhage Secures €2.2M Seed Funding

PrecisionPhage has raised €1M in funding from Nordic Science Investment, Genetricum, and Unifund. Additionally, PrecisionPhage has secured €1.2M in Deep Tech Accelerator funding from Business Finland, which will be disbursed in three phases based on the company's performance.
Read more
News
Mar 4, 2024

PrecisionPhage in the Finnish Media – AMR-Fighting Solutions Seen As an Important Topic

Read more about our company and solutions for combating AMR in Finnish media articles.
Read more
View all
Connect

Get in Touch

Thank you! Your submission has been received!
Something went wrong . Please check the fields and try again.

We're here to assist you with any inquiries you may have. You can also find the all of our team members and their contact info from the team page

Matti Jalasvuori
Matti Jalasvuori
Chief Executive Officer (CEO)
matti.jalasvuori@precisionphage.com
Olli Pitkänen
Olli Pitkänen
Chief Development Officer
olli.pitkanen@precisionphage.com
Ville Hoikkala
Ville Hoikkala
Head of Bioinformatics
ville.hoikkala@precisionphage.com
phage dna genome circle